Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Li Auto Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.7 (market cap $29.60B), while Li Auto Inc trades at $12.5 (market cap $12.28B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.4× Li Auto Inc's market cap. Which is the better fit depends on your goals.
| ALNY | LI | |
|---|---|---|
Market Cap | $29.60B | $12.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $26.69 |
52-Week Low | $205.48 | $11.74 |
Enterprise Value | $27.56B | $1.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Li Auto (LI) trades at $12.505, down 2.61% on the day, with a bearish technical signal and mixed earnings performance. Recent quarterly results show misses on EPS estimates, while revenue declined to $112.31 billion in 2025. The company maintains strong delivery growth, with 30,468 vehicles delivered in July 2026, but faces intense competition in China's EV market. Cash flow trends indicate operational challenges, with negative net cash flow of $9.00 billion in 2025.
Outlook remains cautious due to profitability pressures and competitive headwinds, though analyst consensus suggests moderate upside to a $14.80 price target. Key risks include execution on new model launches and macroeconomic volatility in the EV sector. The stock's current valuation metrics, such as a P/S of 0.83, may appeal to value-oriented investors if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
